Phase 2 N=81 Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
COPD Exacerbation
Primary: Number of Moderate to Severe Exacerbation (Defined as Requiring Treatment With Systemic Corticosteroids and/or Antibiotics in the Community or Hospital or…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Primary: Number of Participants With a Complete Response — 5; 5; 10; 0 Participants
Phase 2 N=155 A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Gastric Cancer
Primary: Progression-Free Survival (PFS) — 9.5; 7.4 months — p=0.0727
Phase 2 N=61 Safety and Efficacy of DA-9805 for Parkinson's Disease
Parkinson's Disease
Primary: Change in Motor MDS-UPDRS Score From Baseline at Week 12 — 1.4; -0.9; -1.2 score on a scale — p=0.3656
Phase 2 N=16 Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Primary: Complete Response (CR or CRi) — 0 proportion of participants
Phase 2 N=20 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
Phase 2 N=17 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell Leukemia · Plasma Cell Myeloma · Plasmacytoma
Primary: Confirmed Response Rate — 0.06 proportion of patients
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 2 N=365 A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
Insomnia Disorders
Primary: Change From Baseline in Latency to Persistent Sleep (LPS) as Measured by Polysomnography (PSG) on Night 1 — -15.24; -29.92; -49.49; -47.69 Minutes — p== 0.346
Phase 2 N=8 Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…
Phase 2 N=25 Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
Peanut Allergy
Primary: Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24 — 8.3 Percentage of Participants
Phase 2 N=295 Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Renal Cell Carcinoma · Melanoma
Primary: Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A) — 36.4; 25; 20; 0.0 Percentage of Participants
Phase 2 N=36 Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Prostate Adenocarcinoma
Primary: Percent of Patients With a Prostate-specific Antigen (PSA) Decline of at Least 50% Below Baseline PSA50 Response Rate — 14 Participants
Phase 2 N=2 Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
Estrogen Receptor and/or Progesterone Receptor Positive · HER2/Neu Negative · Stage IV Breast Cancer AJCC v6 and v7
Primary: Number of Participants With Grade 2 and Above Toxicities Attributed to Ribociclib — 2 Participants
Phase 2 N=192 A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
Thrombosis
Primary: Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events — 1; 3 Participants